全文获取类型
收费全文 | 22035篇 |
免费 | 1371篇 |
国内免费 | 114篇 |
专业分类
耳鼻咽喉 | 314篇 |
儿科学 | 1254篇 |
妇产科学 | 699篇 |
基础医学 | 2488篇 |
口腔科学 | 431篇 |
临床医学 | 2205篇 |
内科学 | 4369篇 |
皮肤病学 | 835篇 |
神经病学 | 1652篇 |
特种医学 | 619篇 |
外科学 | 3042篇 |
综合类 | 658篇 |
一般理论 | 9篇 |
预防医学 | 1906篇 |
眼科学 | 423篇 |
药学 | 1223篇 |
1篇 | |
中国医学 | 17篇 |
肿瘤学 | 1375篇 |
出版年
2021年 | 177篇 |
2019年 | 186篇 |
2018年 | 219篇 |
2017年 | 202篇 |
2016年 | 207篇 |
2015年 | 248篇 |
2014年 | 323篇 |
2013年 | 505篇 |
2012年 | 666篇 |
2011年 | 750篇 |
2010年 | 427篇 |
2009年 | 483篇 |
2008年 | 662篇 |
2007年 | 679篇 |
2006年 | 671篇 |
2005年 | 669篇 |
2004年 | 554篇 |
2003年 | 523篇 |
2002年 | 524篇 |
2001年 | 521篇 |
2000年 | 530篇 |
1999年 | 488篇 |
1998年 | 314篇 |
1997年 | 336篇 |
1996年 | 309篇 |
1995年 | 282篇 |
1994年 | 269篇 |
1993年 | 242篇 |
1992年 | 445篇 |
1991年 | 448篇 |
1990年 | 462篇 |
1989年 | 454篇 |
1988年 | 349篇 |
1987年 | 394篇 |
1986年 | 382篇 |
1985年 | 358篇 |
1984年 | 260篇 |
1983年 | 279篇 |
1982年 | 170篇 |
1979年 | 233篇 |
1978年 | 167篇 |
1977年 | 166篇 |
1976年 | 175篇 |
1959年 | 354篇 |
1958年 | 761篇 |
1957年 | 870篇 |
1956年 | 779篇 |
1955年 | 809篇 |
1954年 | 782篇 |
1949年 | 184篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Mark S. Wallace Steven G. Charapata Robert Fisher Michael Byas‐Smith Peter S. Staats Martha Mayo Dawn McGuire David Ellis 《Neuromodulation》2006,9(2):75-86
Objective. The safety and efficacy of intrathecal (IT) ziconotide was studied in a randomized, double‐blind, placebo‐controlled trial. Materials and Methods. Patients (169 ziconotide, 86 placebo) with severe chronic nonmalignant pain unresponsive to conventional therapy and a visual analog scale of pain intensity (VASPI score) ≥ 50 mm were treated over a 6‐day period in an inpatient hospital setting. Initial starting dose was 0.4 µg/hour and was titrated to analgesia or intolerance (maximum dose 7.0 µg/hour). The starting and maximum doses were reduced to 0.1 µg/hour and 2.4 µg/hour, respectively, due to adverse events (AEs). Results. The mean percent reduction in VASPI score from baseline was 31.2% and 6.0% for ziconotide‐ and placebo‐treated patients, respectively (p ≤ 0.001). During the initial titration phase, a significantly greater percentage of patients in the ziconotide group compared to the placebo group reported AEs, including abnormal gait, amblyopia, dizziness, nausea, nystagmus, pain, urinary retention, and vomiting. Conclusion. Ziconotide provided significant analgesia in patients for whom conventional therapy failed. However, there was a considerable incidence of ziconotide‐associated AEs due to the rapid titration and high doses administered. 相似文献
4.
Edwin B. Fisher Jr. 《Addictive behaviors》1997,22(6):680
The commodity model of social support and features of Nondirective Support may clarify varied results of support interventions for smoking cessation. A commodity model views social support as attractive in and of itself and as an alternative to high-risk choices such as smoking. If such support is easily accessible, a would-be quitter is less likely to choose to smoke. Consistent with the commodity model, social support interventions tend to be effective as long as support remains available, but they lose their effects when support is terminated. From a second approach, Nondirective Support entails accepting recipients' goals, cooperating without taking control, and validating recipients' feelings. In contrast, Directive Support entails taking control and telling recipients what to do and feel. Review of support interventions indicates the value of the continued availability of support suggested by the commodity model and of Nondirective Support's flexibility and responsiveness to the person. 相似文献
5.
Restriction fragment length polymorphism of human mitochondrial DNA in a sample population from Apulia (Southern Italy) 总被引:8,自引:1,他引:7
Restriction fragment length polymorphism (RFLP) of human mitochondrial DNA was analysed in a sample of 87 subjects from Apulia (South Italy) by the restriction enzymes Hpa I, Bam HI, Hae II, Msp I, Ava II, and Hinc II using total blood cell DNA probed by human mtDNA from placenta. Five BamHI morphs were observed, two of which are new ( Bam HI-4 and -5), as well as one new Ava II morph ( Ava II-28). The association Bam HI-4/ Ava II-28 enables us to demonstrate for the first time two polymorphic Bam HI sites present together in the same mtDNA molecule. In agreement with historical data the Apulian sample has been shown to be the most heterogeneous Italian population so far tested. 相似文献
6.
GIUSEPPE PERSEO MAURO GIGLI ROBERTO DE CASTIGLIONE 《Chemical biology & drug design》1987,29(4):478-485
The synthesis of TPH-13 (Glp-Glu-Lys-Pro-Tyr-Trp-Pro-Pro-Pro-Ile-Tyr-Pro-Met-OH), a tridecapeptide isolated from the skin of the South American frog Phyllomedusa rohdei, is described and alternative approaches are discussed. 相似文献
7.
Intratemporal vascular tumors: detection with CT and MR imaging 总被引:1,自引:0,他引:1
Lo WW; Shelton C; Waluch V; Solti-Bohman LG; Carberry JN; Brackmann DE; Wade CT 《Radiology》1989,171(2):445-448
The diagnostic contributions of computed tomography (CT) and magnetic resonance (MR) imaging were compared in 12 patients with benign intratemporal vascular tumors (hemangioma or vascular malformation). The tumors included six in the internal acoustic canal and six in the geniculate ganglion region. Clinical and histologic correlations were made. Two of the six patients with tumors in the internal acoustic canal underwent CT, and both required gas cisternography to show the tumor. Five patients in that group underwent MR imaging, and all five studies showed the tumor. All six patients with geniculate ganglion tumors underwent CT. Results in one study were questionable, and five showed the tumor. Five patients in this group underwent MR imaging, but the MR findings were positive in only two cases. MR imaging should therefore be performed before CT in the evaluation of facial nerve dysfunction, as it demonstrated all tumors in the internal acoustic canal and some in the geniculate ganglion region. If MR findings are negative, CT should then be performed to rule out a possible geniculate ganglion lesion. 相似文献
8.
Yubin Miao Said D Figueroa Darrell R Fisher Herbert A Moore Richard F Testa Timothy J Hoffman Thomas P Quinn 《Journal of nuclear medicine》2008,49(5):823-829
Peptide-targeted alpha-therapy with 7.4 MBq of (212)Pb-[1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]-ReO-[Cys(3,4,10),d-Phe(7),Arg(11)]alpha-MSH(3-13) ((212)Pb-DOTA-Re(Arg(11))CCMSH) cured 45% of B16/F1 murine melanoma-bearing C57 mice in a 120-d study, highlighting its melanoma treatment potential. However, there is a need to develop an imaging surrogate for patient-specific dosimetry and to monitor the tumor response to (212)Pb-DOTA-Re(Arg(11))CCMSH therapy. The purpose of this study was to evaluate the potential of (203)Pb-DOTA-Re(Arg(11))CCMSH as a matched-pair SPECT agent for (212)Pb-DOTA-Re(Arg(11))CCMSH. METHODS: DOTA-Re(Arg(11))CCMSH was labeled with (203)Pb in 0.5 M NH(4)OAc buffer at pH 5.4. The internalization and efflux of (203)Pb-DOTA-Re(Arg(11))CCMSH were determined in B16/F1 melanoma cells. The pharmacokinetics of (203)Pb-DOTA-Re(Arg(11))CCMSH was examined in B16/F1 melanoma-bearing C57 mice. A micro-SPECT/CT study was performed with (203)Pb-DOTA-Re(Arg(11))CCMSH in a B16/F1 melanoma-bearing C57 mouse at 2 h after injection. RESULTS: (203)Pb-DOTA-Re(Arg(11))CCMSH was easily prepared in NH(4)OAc buffer and completely separated from the excess nonradiolabeled peptide by reversed-phase high-performance liquid chromatography (RP-HPLC). (203)Pb-DOTA-Re(Arg(11))CCMSH displayed fast internalization and extended retention in B16/F1 cells. Approximately 73% of (203)Pb-DOTA-Re(Arg(11))CCMSH activity internalized after a 20-min incubation at 25 degrees C. After incubation of the cells in culture medium for 20 min, 78% of internalized activity remained in the cells. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a biodistribution pattern similar to that of (212)Pb-DOTA-Re(Arg(11))CCMSH in B16/F1 melanoma-bearing mice. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a peak tumor uptake of 12.00+/-3.20 percentage injected dose per gram (%ID/g) at 1 h after injection. The tumor uptake gradually decreased to 3.43+/-1.12 %ID/g at 48 h after injection. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a peak tumor-to-kidney uptake ratio of 1.53 at 2 h after injection. The absorbed doses to the tumor and kidneys were 4.32 and 4.35 Gy, respectively, per 37 MBq. Whole-body clearance of (203)Pb-DOTA-Re(Arg(11))CCMSH was fast, with approximately 89% of the injected activity cleared through the urinary system by 2 h after injection. (203)Pb showed 1.6-mm SPECT resolution, which was comparable to (99m)Tc. Melanoma lesions were visualized through SPECT/CT images of (203)Pb-DOTA-Re(Arg(11))CCMSH at 2 h after injection. CONCLUSION: (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited favorable pharmacokinetic and tumor imaging properties, highlighting its potential as a matched-pair SPECT agent for (212)Pb-DOTA-Re(Arg(11))CCMSH melanoma treatment. 相似文献
9.
L. TIMMER-DE MIK M.D. D.M. BROEKHUIJSEN-VAN HENTEN M.D. † J.M. OLDHOFF M.D. PH.D. D.B. DE GEER M.D. ‡ V. SIGURDSSON M.D. PH.D. S.G.M.A. PASMANS M.D. PH.D. 《Pediatric dermatology》2009,26(3):358-360
Abstract: In Sweet's syndrome, the essential features are the characteristic morphology of the lesions, their histologic appearance, the dramatic response to corticosteroids and the absence of scarring. We report an 8-month-old infant in whom Sweet's syndrome was diagnosed and who developed acquired cutis laxa in the skin lesions. 相似文献
10.
R.A. Fisher 《Transplant infectious disease》2009,11(3):195-202
Abstract: As the most prevalent pathogen among transplant patients, cytomegalovirus (CMV) affects up to three-quarters of all solid organ transplant recipients. While we have made great strides in preventing CMV infection and disease in the early post-transplant period, late CMV infection and indirect effects due to viral immunomodulation remain problematic. Changing immunosuppression practices, including the increasing use of T-cell depleting induction antibodies, have the potential to affect the risk for CMV infection and disease, even in the face of good prophylactic and preemptive therapy. The purpose of this review article is to discuss the impact of CMV infection on long-term allograft outcomes and to re-evaluate the risks and management strategies for prevention of CMV in the framework of evolving modern immunosuppressive strategies. 相似文献